Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
October, 2026
October 2026
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Cedric Hermans: Proposing a New 3-tier Framework for FVIII Replacement Therapy in Hemophilia A
Cedric Hermans/institutroialbertdeux.be
May 19, 2026, 15:52

Cedric Hermans: Proposing a New 3-tier Framework for FVIII Replacement Therapy in Hemophilia A

Cedric Hermans, Head of Haemophilia Centre at the Saint-Luc University Hospital, Brussels, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in Blood Advances, adding:

“FVIII therapy classification may need to evolve.

We propose a new 3-tier framework for FVIII replacement therapy in hemophilia A:

  • SHL-FVIII
  • EHL-FVIII
  • HSA/UL-FVIII (high-sustained-activity and ultralong half-life FVIII)

Unlike current EHL products, which remain limited by VWF binding, HSA/UL-FVIII achieves markedly prolonged activity and sustained FVIII levels in or near the nonhemophilia range for several days with once-weekly dosing.

These findings support moving beyond half-life alone and incorporating new exposure-based metrics such as time above threshold and segmented AUC to better characterize next-generation FVIII therapies.”

Title: A revised classification of FVIII concentrates: rationale and novel metrics

Authors: Cedric Hermans, Pratima Chowdary, Barbara A. Konkle, Johnny Mahlangu, Axel Facius, Maria Elisa Mancuso

Cedric Hermans

Other posts featuring Cedric Hermans on Hemostasis Today.

AUC Axel Facius Barbara A. Konkle bleeding bleeding disorders Blood Cedric Hermans EHL FVIII FVIII Therapy Health Hematology Hemophilia Hemophilia A Hemostasis Hemostasis News Hemostasis Today HSA Johnny Mahlangu Maria Elisa Mancuso Medicine Pratima Chowdary UL-FVIII VWF
NewsFeed